David A. Katz
Abbott Laboratories
Abbott Park
IL 60064
USA
Name/email consistency: high
- Clinical observation of liver chemistry abnormalities in asthmatics. Katz, D.A., Isaacson, J.D., Han, L., Drajesk, J.F., Comer, G.M., Heath-Chiozzi, M.E. Curr. Drug. Saf (2009)
- Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Katz, D.A., Murray, B., Bhathena, A., Sahelijo, L. Nat. Rev. Drug. Discov (2008)
- Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Katz, D.A., Carr, R., Grimm, D.R., Xiong, H., Holley-Shanks, R., Mueller, T., Leake, B., Wang, Q., Han, L., Wang, P.G., Edeki, T., Sahelijo, L., Doan, T., Allen, A., Spear, B.B., Kim, R.B. Clin. Pharmacol. Ther. (2006)
- CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Katz, D.A., Grimm, D.R., Cassar, S.C., Gentile, M.C., Ye, X., Rieser, M.J., Gordon, E.F., Polzin, J.E., Gustavson, L.E., Driscoll, R.M., O'dea, R.F., Williams, L.A., Bukofzer, S. Clin. Pharmacol. Ther. (2004)